Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD) | Region

This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention

Related Keywords

San Antonio ,Texas ,United States ,Milan ,Lombardia ,Italy ,American ,Italian ,Paula Pohlmann ,Michael Guy ,Magdalena Biosciences ,Eric Roeland ,Lisa Conte ,Sandram Swain ,Pabloc Okhuysen ,Lombardi Comprehensive Cancer Center ,Jaguar Health ,American Cancer Society ,Jaguar Animal Health ,Breast Cancer Research ,Genentech Inc ,Jaguar Health Inc ,Jaguar Health Family Of Companies ,Filament Health Corp ,Md Anderson Cancer Center ,Jaguar Entheogen Therapeutics Initiative ,Multinational Association Of Supportive Care In Cancer ,Georgetown University ,Napo Pharmaceuticals ,Puma Biotechnology Inc ,Puma Biotechnology ,Neratinib Associated Diarrhea ,Patients With ,Early Stage Breast ,Clinical Breast Cancer ,Winterhof Family Professor ,Breast Oncology ,Scientific Advisory ,Randomized Open Label Phase ,Positive Breast Cancer Receiving Trastuzumab ,Lombardi Comprehensive Cancer ,Antonio Breast Cancer Symposium ,Associate Professor ,Multinational Association ,Supportive Care ,Cancer Therapies ,Cancer Therapy Related Diarrhea ,American Cancer ,Jaguar Health Family ,Napo Therapeutics ,Animal Health ,Filament Health ,Entheogen Therapeutics Initiative ,Minor Use ,Major Species ,Safety Information About Canalevia ,Region ,